Patents by Inventor Masaud SHAH

Masaud SHAH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240059741
    Abstract: The present invention relates to a composition for prevention or treatment of SARS-CoV-2 infection. CSNP1, CSNP2, CSNP3, and CSNP4 bind to receptor the binding domain (RBD) of the spike protein of SARS-CoV-2 to inhibit the interaction of the spike protein of SARS-CoV-2 with ACE2, thereby interfering with the mechanism that SARS-CoV-2 enters cells or evades immunity. Thus, a composition comprising CSNP1, CSNP2, CSNP3, or CSNP4 as an active ingredient is provided as a pharmaceutical agent for prevention or treatment of SARS-CoV-2 infection (COVID19).
    Type: Application
    Filed: December 24, 2021
    Publication date: February 22, 2024
    Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Hyun Goo WOO, Masaud SHAH, Sung Ung MOON
  • Publication number: 20220257782
    Abstract: A peptide inhibiting a Toll-like receptor (TLR) signaling pathway is disclosed. The peptide strongly binds to a TIR-containing molecule to inhibit the TLR, in particular, the TLR4 signaling pathway. A fusion peptide in which a cell-penetrating peptide is conjugated to said peptide; a TLR4 antagonist comprising said peptide or said fusion peptide; and compositions and methods for preventing or treating autoimmune diseases or inflammatory diseases are disclosed. The peptide exhibits an inhibitory effect on a wide range of TLR signaling pathways including TLR4, blocks MyD88- and TRIF-dependent TLR4 pathways, and has a substantial disease-alleviating effect in mouse models of rheumatoid arthritis, psoriasis, systemic lupus erythematosus, and non-alcoholic steatohepatitis, and thus can be usefully utilized as therapeutics for immune-related diseases and inflammatory diseases that require negative control of TLR.
    Type: Application
    Filed: June 30, 2020
    Publication date: August 18, 2022
    Applicant: GENESEN CO., LTD.
    Inventors: Sang Dun CHOI, Chang Hee SUH, Wook KIM, Masaud SHAH, Asma ACHEK, Giyoung KIM, Jae Youn CHEONG, Soon Sun KIM
  • Patent number: 11186612
    Abstract: A substance P analog having a progenitor cell or stem cell recruiting activity and a method of recruiting progenitor cells or stem cells using the substance P analog are disclosed. The substance P analog has an effect of recruiting endogenous progenitor cells or stem cells to a wound or disease-occurring site. Thus, the disclosure also describes its use in recruiting progenitor cells or stem cells and a method of regenerating or treating a damaged organ or tissue, or a method of healing a wound.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: November 30, 2021
    Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Moon Suk Kim, Sang Dun Choi, Seung Hun Park, Masaud Shah
  • Publication number: 20200299330
    Abstract: A substance P analog having a progenitor cell or stem cell recruiting activity and a method of recruiting progenitor cells or stem cells using the substance P analog are disclosed. The substance P analog has an effect of recruiting endogenous progenitor cells or stem cells to a wound or disease-occurring site. Thus, the disclosure also describes its use in recruiting progenitor cells or stem cells and a method of regenerating or treating a damaged organ or tissue, or a method of healing a wound.
    Type: Application
    Filed: April 24, 2020
    Publication date: September 24, 2020
    Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Moon Suk KIM, Sang Dun CHOI, Seung Hun PARK, Masaud SHAH